- Home
- DVAX vs WAL Comparison
DVAX vs WAL Comparison
Compare DVAX & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- WAL
- Stock Information
- Founded
- DVAX 1996
- WAL 1994
- Country
- DVAX United States
- WAL United States
- Employees
- DVAX N/A
- WAL N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- WAL Major Banks
- Sector
- DVAX Health Care
- WAL Finance
- Exchange
- DVAX Nasdaq
- WAL Nasdaq
- Market Cap
- DVAX 1.3B
- WAL 10.1B
- IPO Year
- DVAX 2004
- WAL 2005
- Fundamental
- Price
- DVAX $9.75
- WAL $91.53
- Analyst Decision
- DVAX Buy
- WAL Strong Buy
- Analyst Count
- DVAX 4
- WAL 13
- Target Price
- DVAX $26.50
- WAL $97.62
- AVG Volume (30 Days)
- DVAX 2.0M
- WAL 1.1M
- Earning Date
- DVAX 11-06-2025
- WAL 10-16-2025
- Dividend Yield
- DVAX N/A
- WAL 1.66%
- EPS Growth
- DVAX N/A
- WAL 14.60
- EPS
- DVAX N/A
- WAL 7.61
- Revenue
- DVAX $316,268,000.00
- WAL $3,120,700,000.00
- Revenue This Year
- DVAX $23.23
- WAL $14.78
- Revenue Next Year
- DVAX $16.57
- WAL $10.40
- P/E Ratio
- DVAX N/A
- WAL $12.03
- Revenue Growth
- DVAX 26.66
- WAL 10.46
- 52 Week Low
- DVAX $9.20
- WAL $57.05
- 52 Week High
- DVAX $14.63
- WAL $98.10
- Technical
- Relative Strength Index (RSI)
- DVAX 43.66
- WAL 63.37
- Support Level
- DVAX $9.20
- WAL $85.43
- Resistance Level
- DVAX $9.94
- WAL $91.61
- Average True Range (ATR)
- DVAX 0.31
- WAL 2.42
- MACD
- DVAX -0.01
- WAL -0.20
- Stochastic Oscillator
- DVAX 50.00
- WAL 77.54
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.